SCHEMBL8306824

SCHEMBL8306824

COC(=O)c1cc(CO)ccc1CN1[C@@H](c2ncccc2C)CCC[C@H]1c1ncccc1C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.38
ALDH1A1 P00352 3/20 0.38
NPSR1 Q6W5P4 2/20 0.38
POLB P06746 1/20 0.36
CXCR4 P61073 4/20 0.35
OPRK1 P41145 1/20 0.35
CHRM1 P11229 1/20 0.35
IRAK4 Q9NWZ3 1/20 0.34
TP53 P04637 1/20 0.34
BDKRB1 P46663 1/20 0.33
GAA P10253 1/20 0.33
CASP7 P55210 1/20 0.33
CNR2 P34972 1/20 0.33
CSF1R P07333 1/20 0.33
LMNA P02545 1/20 0.33
TSHR P16473 1/20 0.33
MAPK10 P53779 1/20 0.33
PKM P14618 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
CA12 O43570 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2472764 1.00 KDM4E (0.38) KDM4EALDH1A1NPSR1POLBCXCR4
SCHEMBL8301571 0.92 KDM4E (0.37) KDM4EALDH1A1NPSR1POLBCXCR4
SCHEMBL2476951 0.92 KDM4E (0.37) KDM4EALDH1A1NPSR1POLBCXCR4
SCHEMBL2470463 0.89 CXCR4 (0.37) CXCR4OPRK1CHRM1
SCHEMBL2474896 0.89 ALOX15 (0.39) KDM4EALDH1A1NPSR1POLBCXCR4
SCHEMBL2472903 0.89 ALOX15 (0.39) KDM4EALDH1A1NPSR1POLBCXCR4
SCHEMBL2475396 0.88 P2RX7 (0.39) KDM4ECXCR4OPRK1LMNA
SCHEMBL2472806 0.88 P2RX7 (0.39) KDM4EALDH1A1POLBCXCR4CHRM1
SCHEMBL2470095 0.86 KDM4E (0.42) KDM4EALDH1A1POLBCXCR4OPRK1
SCHEMBL8301697 0.86 KDM4E (0.42) KDM4EALDH1A1POLBCXCR4OPRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090281308-A1 CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY ANORMED, INC. (CA) 2009-11-12 US disclosed
US-20090281308-A1 CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY ANORMED, INC. (CA) 2009-11-12 US disclosed
US-7550484-B2 Chemokine receptor binding heterocyclic compounds with enhanced efficacy GENZYME CORPORATION (US) 2009-06-23 US disclosed
US-7550484-B2 Chemokine receptor binding heterocyclic compounds with enhanced efficacy GENZYME CORPORATION (US) 2009-06-23 US disclosed
WO-2004093817-A2 CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY ANORMED INC. (CA) 2004-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281308-A1 CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY CXCR4, CXCR1, CCR5 KDM4E 3731/4885ALDH1A1 290/4885NPSR1 439/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.